Recommendation for improving the use of patient-reported outcomes (PROs) in cardiovascular trials, regulatory and payers' decisions and care. HRQoL, health-related quality of life; PROM, patient-reported outcome measure.

Impact of hypertensive response to exercise on functional capacity and prognosis. Cumulative survival and relative risk of all-cause mortality (ACM) and cardiovascular hospitalizations (CVH) after a median follow-up of 16 months per tertile of systolic blood pressure (SBP)/workload slope. Unadjusted analysis (Kaplan–Meier survival curves) for the primary outcome in the whole patient population. Adjusted analysis (Cox proportional hazard ratios) illustrating higher mortality in the highest tertile of the SBP/workload slope. Hazard ratios are adjusted for age, sex, body mass index, arterial hypertension, diabetes mellitus, previous myocardial infarction, N-terminal pro-B-type natriuretic peptide, rest and peak SBP, rest and peak cardiac output, rest and peak left ventricular ejection fraction, and medications (beta-blockers and calcium channel blockers). AVO₂diff, arterial–venous oxygen content difference; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; VAC, ventricular–arterial coupling; VO₂, oxygen consumption.

In a meta-analysis of ten randomized controlled trials (RCTs) including AFFIRM-AHF and IRONMAN of over 3000 patients with heart failure (HF) and iron deficiency (ID), compared to standard care/placebo, intravenous (IV) iron reduced the primary outcome of recurrent hospitalisations for heart failure (HHF) and cardiovascular mortality (CVM) by 25%. The effect was mainly driven by a reduction in HHF with the effect on CVM being inconconclusive. Created in BioRender.com. Additional icons provided from http://icon-library.com/icon/heart-disease-icon-3.html.html Heart Disease Icon #293840. CI, confidence interval; CVM, cardiovascular mortality; HF, heart failure; HHF, hospitalization for heart failure; I, iron deficiency; IV, intravenous/interval variable; OR, odds ratio; RCT, randomized controlled trial; RR, risk rate; SE, standard error; SoC, standard of care.

Impact of mitral regurgitation (MR) in patients with acute heart failure (HF): an analysis on 6420 patients from RELAX-AHF-2. AF, atrial fibrillation; BNP, B-type natriuretic peptide; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HR, hazard ratio; IV, intravenous; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RF, renal failure; SBP, systolic blood pressure.

Patients with heart failure with moderate-severe/severe mitral regurgitation stratified by serum albumin level. CI, confidence interval; GDMT, guideline-directed medical therapy; HFH, heart failure hospitalization; HR, hazard ratio; TEER, transcatheter edge-to-edge repair.

Use of mechanical circulatory support (MCS) in patients with non-ischaemic cardiogenic shock (CS). CI, confidence interval; HR, hazard ratio.

Treatment of chronic ischaemic heart failure with reduced ejection fraction (HFrEF) patients with allogeneic adipose tissue-derived stromal cells (ASC) was safe but without any demonstratable restoration of cardiac function or clinical symptoms. (A) Kaplan–Meier plot of freedom of cumulative combined cardiac-related adverse events during a 3-year follow-up period. (B) Differences in baseline to 6-month follow-up in left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) in ASC treated compared to placebo patients.